KOPS - The Institutional Repository of the University of Konstanz

COVID-19 vaccines : ethical framework concerning human challenge studies

Aufgrund von Vorbereitungen auf eine neue Version von KOPS, können kommenden Montag und Dienstag keine Publikationen eingereicht werden. (Due to preparations for a new version of KOPS, no publications can be submitted next Monday and Tuesday.)

COVID-19 vaccines : ethical framework concerning human challenge studies

Cite This

Files in this item

Files Size Format View

There are no files associated with this item.

CALINA, Daniela, Thomas HARTUNG, Anca Oana DOCEA, Demetrios A. SPANDIDOS, Alex M. EGOROV, Michael I. SHTILMAN, Felix CARVALHO, Aristidis TSATSAKIS, 2020. COVID-19 vaccines : ethical framework concerning human challenge studies. In: DARU Journal of Pharmaceutical Sciences. Springer. 28(2), pp. 807-812. ISSN 1560-8115. eISSN 2008-2231. Available under: doi: 10.1007/s40199-020-00371-8

@article{Calina2020-12COVID-51106, title={COVID-19 vaccines : ethical framework concerning human challenge studies}, year={2020}, doi={10.1007/s40199-020-00371-8}, number={2}, volume={28}, issn={1560-8115}, journal={DARU Journal of Pharmaceutical Sciences}, pages={807--812}, author={Calina, Daniela and Hartung, Thomas and Docea, Anca Oana and Spandidos, Demetrios A. and Egorov, Alex M. and Shtilman, Michael I. and Carvalho, Felix and Tsatsakis, Aristidis} }

Docea, Anca Oana Egorov, Alex M. eng Calina, Daniela 2020-09-29T12:02:37Z Shtilman, Michael I. COVID-19 vaccines : ethical framework concerning human challenge studies Hartung, Thomas Spandidos, Demetrios A. Carvalho, Felix Background<br />The pandemic associated with the new SARS-CoV-2 coronavirus continues to spread worldwide. The most favorable epidemic control scenario, which provides long-term protection against COVID-19 outbreak, is the development and distribution of an effective and safe vaccine. The need to develop a new COVID-19 vaccine is pressing; however, it is likely to take a long time, possibly several years. This is due to the time required to demonstrate the safety and efficacy of the proposed vaccine. and the time required to manufacture and distribute millions of doses.<br /><br />Objectives<br />To accelerate this development and associated safety testing, the deliberate infection of healthy volunteers has been suggested. The purpose of this short communication is to describe the ethical aspects of this type of testing,<br /><br />Results<br />Deliberate infection of volunteers with a dangerous virus such as SARS-CoV-2 was initially considered unethical by researchers; but the current pandemic is so different from previous ones that these studies are considered ethical if certain criteria are met. Participants in human challenge studies must be relatively young, in good health and must receive the highest quality medical care, with frequent monitoring. Tests should also be performed with great caution and specialized medical supervision. Besides, the fact that obtaining vaccines faster through deliberate infection studies of healthy people has greater benefits than risks, has been demonstrated by obtaining other vaccines in other historical pandemics such as: smallpox, influenza, malaria, typhoid fever, Dengue fever and Zika.<br /><br />Conclusions<br />One possibility to shorten the time required for the development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives. Carvalho, Felix Shtilman, Michael I. Tsatsakis, Aristidis Spandidos, Demetrios A. Egorov, Alex M. terms-of-use 2020-12 Calina, Daniela Docea, Anca Oana Tsatsakis, Aristidis Hartung, Thomas 2020-09-29T12:02:37Z

This item appears in the following Collection(s)

Search KOPS


My Account